Physician profile
Adrian Marimon
NPI 1770718058
$2,779.94
in general payments reported to CMS, 2019-2025
30 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $168 · 2021: $581 · 2022: $687 · 2023: $489 · 2024: $403 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $791.09 | 2021-2025 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Abbvie INC. | $547.84 | 2019-2025 | |
| Hologic Sales and Service, LLC | $165.14 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Mission Pharmacal Company | $133.89 | 2019-2024 | Citranatal, Uribel Tabs |
| Medical Device Business Services, INC. | $119.11 | 2022 | |
| Evofem Biosciences, INC. | $85.86 | 2021-2024 | |
| Becton, Dickinson and Company | $78.72 | 2022-2023 | Bd Onclarity |
| Ethicon US, LLC | $75.61 | 2020-2021 | |
| Astellas Pharma US INC | $73.57 | 2023-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $72.01 | 2024-2025 | Slynd, Tyblume |
| Therapeuticsmd, INC. | $65.16 | 2020-2022 | |
| Allergan, INC. | $65.11 | 2019-2020 | |
| Avion Pharmaceuticals | $64.87 | 2021-2023 | Balcoltra |
| Mylan Pharmaceuticals INC. | $55.64 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $54.15 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $49.58 | 2024-2025 | Pico 14, Renasys Touch |
| Biogen, INC. | $47.55 | 2024-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $40.63 | 2019 | |
| Innovation Technologies INC | $26.97 | 2025 | Irrisept |
| Pfizer INC. | $24.45 | 2025 | |
| Myovant Sciences INC. | $24.44 | 2021 | |
| Shield Therapeutics INC | $23.93 | 2023 | |
| Axonics, INC. | $23.08 | 2023 | Axonics |
| Medicem INC. | $20.58 | 2022 | |
| Millicent US INC | $18.83 | 2021 | |
| Gilead Sciences, INC. | $16.80 | 2025 | |
| Duchesnay USA Incorporated | $15.33 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Marimon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.